Status:
COMPLETED
Translational Control of Anabolic Resistance in Aging Muscle
Lead Sponsor:
University of Utah
Collaborating Sponsors:
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Conditions:
Physical Inactivity
Eligibility:
All Genders
60-85 years
Phase:
NA
Brief Summary
This is an interventional study enrolling older individuals aged 60-85y to observe changes during physical inactivity. This study is investigating the relation between short-term physical inactivity a...
Detailed Description
Pre-testing- The baseline evaluation will assess muscle function and strength, and an oral glucose tolerance test. After the baseline visit, participants will be provided with a step activity monitor ...
Eligibility Criteria
Inclusion
- Age between 60-85 years
- Ability to sign informed consent
- Free-living, prior to admission
Exclusion
- Cardiac abnormalities considered exclusionary by the study physician (e.g., Chronic heart Failure, right-to-left shunt)
- Uncontrolled endocrine or metabolic disease (e.g., hypo/hyperthyroidism, diabetes)
- History of kidney disease or failure
- Vascular disease or risk factors of peripheral atherosclerosis. (e.g., uncontrolled hypertension, obesity, diabetes, hypercholesterolemia \> 250 mg/dl, claudication or evidence of venous or arterial insufficiency upon palpitation of femoral, popliteal and pedal arteries)
- Risk of blood clotting including family history of thrombophilia, pulmonary emboli, myeloproliferative diseases including polycythemia (Hb\>18 g/dL) or thrombocytosis (platelets\>400x103/mL), and connective tissue diseases (positive lupus anticoagulant), hyperhomocystinemia, deficiencies of factor V Leiden, proteins S and C, and antithrombine III
- Use of anticoagulant therapy (e.g., Coumadin, heparin)
- Elevated systolic pressure \>150 or a diastolic blood pressure \> 100
- Cancer or history of successfully treated cancer (less than 1 year) other than basal cell carcinoma
- Implanted electronic devices (e.g., pacemakers, electronic infusion pumps, stimulators)
- Currently on a weight-loss diet or body mass index \> 30 kg/m2
- Chronic systemic corticosteroid use (≥ 2 weeks) within 4 weeks of enrollment and for study duration (intra-articular/topical/inhaled therapeutic or physiologic doses of corticosteroids are permitted). Androgens or growth hormone within 6 months of enrollment and for study duration (topical physiologic androgen replacement is permitted)
- History of stroke with motor disability
- A recent history (\<12 months) of GI bleed
- History of liver disease
- History of respiratory disease (acute upper respiratory infection, history of chronic lung disease)
- Prior history of Heparin-Induced Thrombocytopenia
- An HbA1c value at or greater than 6.5%
- Any other condition or event considered exclusionary by the PI and faculty physician
Key Trial Info
Start Date :
March 5 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 17 2019
Estimated Enrollment :
9 Patients enrolled
Trial Details
Trial ID
NCT03839628
Start Date
March 5 2019
End Date
December 17 2019
Last Update
June 22 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Utah
Salt Lake City, Utah, United States, 84112